{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:26:58Z","timestamp":1777598818718,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.pbb.2013.04.007","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T20:24:36Z","timestamp":1366316676000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Systemic administration of 5-HT2C receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model"],"prefix":"10.1016","volume":"108","author":[{"given":"Shinichi","family":"Ogino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Nagakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Watabiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Oe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2013.04.007_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/eujp.1999.0148","article-title":"Citalopram in patients with fibromyalgia \u2014 a randomized, double-blind, placebo-controlled study","volume":"4","author":"Anderberg","year":"2000","journal-title":"Eur J Pain"},{"key":"10.1016\/j.pbb.2013.04.007_bb0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0002-9343(01)01089-0","article-title":"A randomized, placebo-controlled, double-blind flexible-dose study of fluoxetine in the treatment of women with fibromyalgia","volume":"112","author":"Arnold","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.pbb.2013.04.007_bb0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FBP.0b013e328349aae4","article-title":"The complex role of serotonin and 5-HT receptors in chronic pain","volume":"22","author":"Bardin","year":"2011","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar2005","article-title":"Biology and therapy of fibromyalgia: genetic aspects of fibromyalgia syndrome","volume":"8","author":"Buskila","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pbb.2013.04.007_bb0025","first-page":"423","article-title":"Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice","volume":"46","author":"Chojnacka-W\u00f3jcik","year":"1994","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0030","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0028-3908(87)90110-9","article-title":"Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat","volume":"26","author":"Colpaert","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.04.007_bb0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cne.20667","article-title":"Pre- and postsynaptic localization of the 5-HT7 receptor in rat dorsal spinal cord: immunocytochemical evidence","volume":"490","author":"Doly","year":"2005","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.111.179572","article-title":"Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist","volume":"337","author":"Dunlop","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.04.007_bb0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-005-2190-x","article-title":"Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats","volume":"180","author":"Fern\u00e1ndez-Guasti","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.04.007_bb0060","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pbb.2013.04.007_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-328X(01)00049-3","article-title":"Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata","volume":"89","author":"Fonseca","year":"2001","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-009-1694-1","article-title":"The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis","volume":"212","author":"Fox","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.04.007_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.2042-7158.1993.tb03698.x","article-title":"The effect of reserpine and stress on feeding behaviour in the light and dark phases of the diurnal cycle in rats","volume":"45","author":"Gorka","year":"1993","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002130100801","article-title":"Activation of 5-HT2C receptors reduces the locomotor and rewarding effects of nicotine","volume":"157","author":"Grottick","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.04.007_bb0075","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.106.113357","article-title":"5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation","volume":"320","author":"Hackler","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.04.007_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-2999(75)90327-1","article-title":"Loss of body weight as a predictor of reserpine-induced amine depletion","volume":"32","author":"Halaris","year":"1975","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0085","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2165\/11596680-000000000-00000","article-title":"Serotonergic anti-obesity agents: past experience and future prospects","volume":"71","author":"Halford","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2013.04.007_bb0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.brainres.2004.03.032","article-title":"Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats","volume":"1011","author":"Hayashi","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-004-2019-z","article-title":"Agonist diversity in 5-HT2C receptor-mediated weight control in rats","volume":"178","author":"Hayashi","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2013.04.007_bb0100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuropharm.2006.05.031","article-title":"Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A\/2C receptors","volume":"51","author":"Honda","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.04.007_bb0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0006-8993(02)04055-6","article-title":"Serotonergic signaling inhibits hyperalgesia induced by spinal cord damage","volume":"963","author":"Horiuchi","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.pbb.2010.10.003","article-title":"Combination of escitalopram and a 5-HT(1A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(2C) receptor stimulation; suggestive of antipsychotic potential","volume":"97","author":"Hovels\u00f8","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.04.007_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pbb.2013.04.007_bb0120","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00000542-200205000-00022","article-title":"Intracerebroventricular morphine produces antinociception by evoking gamma-aminobutyric acid release through activation of 5-hydroxytryptamine 3 receptors in the spinal cord","volume":"96","author":"Kawamata","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2013.04.007_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0006-8993(93)91674-H","article-title":"5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals","volume":"612","author":"Kidd","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2003.10.004","article-title":"Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist","volume":"483","author":"Kimura","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0135","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1517\/14656566.2010.507192","article-title":"A review of SSRIs and SNRIs in neuropathic pain","volume":"11","author":"Lee","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pbb.2013.04.007_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00296-010-1678-9","article-title":"Candidate gene studies of fibromyalgia: a systematic review and meta-analysis","volume":"32","author":"Lee","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.pbb.2013.04.007_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-8993(91)90400-P","article-title":"Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord","volume":"550","author":"Marlier","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.106989","article-title":"WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity","volume":"320","author":"Marquis","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.04.007_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(02)00009-6","article-title":"Descending control of pain","volume":"66","author":"Millan","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","article-title":"Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia","volume":"146","author":"Nagakura","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2013.04.007_bb0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbr.2011.09.023","article-title":"Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats","volume":"226","author":"Nagakura","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ejpain.2010.04.008","article-title":"5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain","volume":"14","author":"Nakai","year":"2010","journal-title":"Eur J Pain"},{"key":"10.1016\/j.pbb.2013.04.007_bb0175","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neulet.2010.01.080","article-title":"Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia","volume":"472","author":"Nishiyori","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pbb.2013.04.007_bb0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pain.2003.12.019","article-title":"Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury","volume":"108","author":"Obata","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2013.04.007_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.03.029","article-title":"Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in the rats with peripheral nerve injury","volume":"567","author":"Obata","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0190","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.neuroscience.2010.06.061","article-title":"Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats","volume":"169","author":"Oe","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2013.04.007_bb0195","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity"},{"key":"10.1016\/j.pbb.2013.04.007_bb0200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.amjmed.2006.06.006","article-title":"A randomized, controlled, trial of controlled release paroxetine in fibromyalgia","volume":"120","author":"Patkar","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.pbb.2013.04.007_bb0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pbb.2013.04.007_bb0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0215","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0028-3908(84)90097-2","article-title":"5-Hydroxytryptamine and antinociception","volume":"23","author":"Roberts","year":"1984","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.04.007_bb0220","first-page":"104","article-title":"Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia\/fibrositis syndrome","volume":"19","author":"Russell","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0225","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pbb.2013.04.007_bb0230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0304-3959(03)00115-5","article-title":"Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats","volume":"104","author":"Sch\u00e4fers","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2013.04.007_bb0240","first-page":"S106","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of vabicaserin in subjects with acute exacerbation of schizophrenia","volume":"36","author":"Shen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2013.04.007_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1471-4159.1988.tb04845.x","article-title":"Extracellular amino acid concentrations in the dorsal spinal cord of freely moving rats following veratridine and nociceptive stimulation","volume":"51","author":"Skilling","year":"1988","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2013.04.007_bb0245","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.04.007_bb0250","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/art.24000","article-title":"A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome","volume":"59","author":"Uceyler","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pbb.2013.04.007_bb0255","first-page":"438","article-title":"Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases","volume":"11","author":"Wacker","year":"2008","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.pbb.2013.04.007_bb0260","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1074\/jbc.M111.277871","article-title":"Hypothalamic Ahi1 mediates feeding behavior through interaction with 5-HT2C receptor","volume":"287","author":"Wang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pbb.2013.04.007_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/03009749409103725","article-title":"A double-blind placebo controlled trial of fluoxetine in fibromyalgia","volume":"23","author":"Wolfe","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0270","first-page":"555","article-title":"Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population","volume":"24","author":"Wolfe","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pbb.2013.04.007_bb0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1254\/jphs.CRJ06008X","article-title":"Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord","volume":"101","author":"Yoshimura","year":"2006","journal-title":"J Pharmacol Sci"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:47:50Z","timestamp":1745992070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305713001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":55,"alternative-id":["S0091305713001019"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2013.04.007","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic administration of 5-HT2C receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2013.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}